Shots:

• The initiation of the post-exposure prophylaxis clinical trial follows Korean MFDS’ IND approval on Oct 08- 2020
• The study will assess the preventive effect & safety of CT-P59 in ~1000 patients and whether CT-P59 can elicit a neutralizing Ab response to prevent the virus from infecting human cells
• Celltrion will continue to generate data from ongoing clinical trials of CT-P59 in various clinical settings. CT-P59 has demonstrated promising safety results in the P-I clinical trial in healthy volunteers
  
    Ref: Celltrion | Image: Celltrion